Effect of a new ultrashort betalytic agent on aconitine-induced arrhythmia. 2005

Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
Department of Human Pharmacology and Toxicology, University of Veterinary and Pharmaceutical Sciences, 612 42 Brno, Czech Republic. bartosoval@vfu.cz

The anti-arrhythmic effect was tested on the model of aconitine-induced arrhythmia. The experiment was performed in vivo with 31 male Wistar laboratory rats. Group A was first administered aconitine and, after the onset of the first sinus rhythm disorders, the 44Bu compound was administered. Group B was first administered the 44Bu compound and only after that the aconitine. The control group was administered aconitine and saline as a replacement of the tested compound. In group A, there was a decrease in the ventricular fibrillation occurrence from 100 % to 8 % (p < 0.001) after the administration of the 44Bu compound. In the B group, the onsets of all monitored arrhythmia types were delayed by an average of 15.6 min. Ventricular rhythm occurrence was decreased from 100 to 20 %, as well as ventricular fibrillations, from 100 to 0 % (p < 0.001).

UI MeSH Term Description Entries
D008297 Male Males
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000157 Aconitine A C19 norditerpenoid alkaloid (DITERPENES) from the root of ACONITUM; DELPHINIUM and larkspurs. It activates VOLTAGE-GATED SODIUM CHANNELS. It has been used to induce ARRHYTHMIAS in experimental animals and it has anti-inflammatory and anti-neuralgic properties. Acetylbenzoylaconine,Aconitane-3,8,13,14,15-pentol, 20-ethyl-1,6,16-trimethoxy-4-(methoxymethyl)-, 8-acetate 14-benzoate, (1alpha,3alpha,6alpha,14alpha,15alpha,16beta)-,Acetylbenzoyl-aconine,Acetylbenzoyl aconine
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001145 Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac
D001565 Benzoates Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure. Benzoate,Benzoic Acids,Acids, Benzoic
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
January 1958, British heart journal,
Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
September 1958, Ceskoslovenska fysiologie,
Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
January 2013, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
September 1989, The Journal of pharmacy and pharmacology,
Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
February 1987, Zhonghua xin xue guan bing za zhi,
Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
January 1971, Comptes rendus des seances de la Societe de biologie et de ses filiales,
Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
December 1971, Japanese journal of pharmacology,
Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
December 2007, European journal of pharmacology,
Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
January 1978, Acta physiologica latino americana,
Ladislava Bartosová, and Filip Novák, and Marek Frydrych, and Tomás Parák, and Radka Opatrilová, and Vít Brunclík, and Jana Kolevská, and Elnaggar El Moataz, and Jirí Necas
February 1989, Fiziologicheskii zhurnal SSSR imeni I. M. Sechenova,
Copied contents to your clipboard!